Lymphoma

Latest News

China’s NMPA Approves Tafasitamab/Lenalidomide in ASCT-Ineligible DLBCL

May 22nd 2025

Tafasitamab is the first CD19 antibody approved in China for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

The FDA’s ODAC convened to discuss the potentially inconsistent treatment effects of glofitamab between regional subgroups in the phase 3 STARGLO trial.

FDA ODAC Votes 8-to-1 Against Applicability of Glofitamab DLBCL Data

By Russ Conroy

May 20th 2025

Addressing Real-World Use of Liso-Cel vs Axi-Cel in DLBCL

By ONCOLOGY Staff

May 17th 2025

Among 18 patients with central nervous system lymphoma treated with the ibrutinib/ nivolumab combination regimen, 3 were in remission beyond 2 years.

Ibrutinib/Nivolumab Shows Clinical Activity in R/R CNS Lymphoma

By Roman Fabbricatore

May 14th 2025

Loncastuximab Tesirine Combo Demonstrates Early Efficacy in R/R DLBCL

By Roman Fabbricatore

May 14th 2025

Latest CME Events & Activities

Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy

Go To PER in Chicago

May 30, 2025 - June 3, 2025

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

BURST Expert Illustrations and Commentaries™: Exploring the Mechanistic Rationale for CSF-1R– Directed Treatment in Chronic GVHD

(CME) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care

(COPE) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care

Community Practice Connections™: 6th Annual Precision Medicine Symposium – An Illustrated Tumor Board

Medical Crossfire®: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes

...

56 57 58 59 60

Do Not Sell My Personal Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777